Hear from insiders how modular construction, new production platforms and single-use technology are reducing the risk, and time, required for new biopharmaceutical manufacturing facility construction and startup. Learn true cost vs benefits, and distinguish between myth and reality in terms of equipment and platform capabilities and versatility. Manufacturing floor issues will also be discussed in depth, individual facility installations will be analyzed, sharing best practices and lessons learned.
Biopharma solution providers are increasingly being asked to provide broad, scalable processing offerings. At Interphex 2012, Paul Lubas, senior marketing manager for 3M Purification, talks about how his company has expanded upon its traditional life sciences product families to now include a diverse "wheel" of solutions.
Pharmaceutical Manufacturing Editor in Chief Agnes Shanley discusses trends in the industry's use of PAT and QbD with Emerson Process Management's Director of Life Sciences Chris Amstutz. The industry has moved beyond "kicking the tires" of QbD, Amstutz says.
At Interphex 2012, Jim Botkin, Senior VP of Operations for Alkermes plc, discusses the extent of his organization's services and capabilities following the recent merger with Elan Drug Technologies. Botkin also discusses the importance of risk-based compliance to the success of any contract partnership. "GMP is good business," he says.
Pharmaceutical Manufacturing's Paul Thomas discusses the most recent fluid control system technologies with Burkert Field Segment Manager, Rick Zinkowski. For more information visit www.burkert-usa.com.
At Interphex 2012, Sean Peterson of Central Research Laboratories demonstrates his company's latest technologies for glove boxes, transfer ports, and isolation. The emphasis is on operator safety and dexterity, he tells Pharmaceutical Manufacturing's Michele V. Wagner.
At Interphex 2012, Matt Bundenthal of Fette Compacting America shows off the company's new FE55 tablet press. The product was designed with the operator in mind, to simplify changeover, operations, and maintenance. In addition, the machine's automation capabilities far exceed what was available in the past, Bundenthal notes.
At Interphex 2012, Xcellerex founder and CTO Parrish Galliher talks about the drug industry's adoption of his company's FlexFactory technology since it was commercialized a few years ago. Four FlexFactories have now been sold worldwide, Galliher says, by companies in different regions and with diverse needs. Speaking with Pharmaceutical Manufacturing's Paul Thomas, Galliher provides a complete, end-to-end tour of FlexFactory.
At Interphex 2012, Daniel Lachapelle, managing director for Foster Wheeler Biokinetics, provides an update on his company's core competencies in engineering, design, construction, and validation of biopharmaceutical facilities. Speaking with Pharmaceutical Manufacturing's Senior Editor Paul Thomas, he shares pain points that life sciences manufacturers are experiencing in meeting the needs of today's global, yet local drug markets.
At Interphex 2012, Patheon's Geoffrey Glass and Softigel's Alvaro Franco discuss their companies' new collaboration to offer customers P-Gels, or prescription softgels and other new technologies that have not previously been available within pharmaceutical contract manufacturing. New, innovative products include varieties of gelatin-coated tablets, VeggieGels, and twist-off capsules.
Join us for a review and moderated discussion of the issues and technologies driving new pharmaceutical manufacturing facility design and construction, both in the U.S. and in growing Asian markets. Among the questions, in the U.S. are: where are the facilities being built and how will that affect industry employment trends? How are they being designed?
Biopharmaceutical manufacturers are reducing risk and cost by using modular construction, disposable process equipment, contained equipment and other innovations. Will they change the industry's approach to plant design and engineering?
Transferability of experimental methods is a problem for industrial and academic labs alike, wasting millions of dollars each year. The Journal of Visualized Experiments (JoVE) uses video to help transfer the knowledge required to carry out lab experiments successfully. Co-founder Moshe Pritsker discusses its business model, industry issues and how the journal works.
Recent high-profile product recalls and counterfeiting cases have drawn attention to the need for drug manufacturers to work across the entire supply chain to ensure product safety and quality. Join Brian Johnson, Pfizer Senior Director of Supply Chain Security, and consultant Russ Somma, in a webcast discussion of best practices for ensuring supply chain security.
Outsourcing and offshoring are touchy subjects for any community anxious about losing potential industry and jobs. A study in November's issue of the Journal of Operations Management suggests that quality risks increase when operations are moved offshore, but emphasizes the fact that this is a knowledge management problem. Lead author, Professor John Gray of Ohio State University's Fisher College of Business, discusses the study, industry reaction, misunderstandings and upcoming research on this important, but difficult, topic.